Skip to main content

Galapagos in Antiviral Discovery Collaboration with Boehringer Ingelheim

NEW YORK, Nov. 11 (GenomeWeb News) - Galapagos Genomics said today that it has entered into a collaboration with Boehringer Ingelheim in the field of antiviral discovery research.

Boehringer Ingelheim will use Galapagos' SilenceSelect platform - a collection of adenoviruses with siRNA-based knockdown sequences targeting over 4,000 human genes -- to perform a genome-wide screen for all drugable genes that influence viral replication in human cells, Galapagos said.

Galapagos said it will receive up-front technology access fees and will be eligible for further license fees during the program. Further financial terms were not disclosed.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.